Irinotecan in the treatment of small cell lung cancer

References

• Aisner J, Alberto P, Bitran J et al. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat. Res. 67, 37–43 (1983).
   Google Scholar
• Stahel RA, Ginsberg R, Havemann K et al. Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer5, 119–126 (1989).
   Google Scholar
• Kelly K. New chemotherapy agents for small cell lung cancer. Chest 117, 156S-162S (2000).
   Google Scholar
• Fukuoka M, Furuse K, Saijo N eta]. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. Natl Cancer Inst. 83, 855–861 (1991).
   Google Scholar
• Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cydophosphamide, doxorubicin and vincristine versusetoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a Phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol 10, 282–291 (1992).
   Google Scholar
• Pignon JP, Arriagada R, Ihde DC et al A Meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl. J. Med. 327, 1618–1624 (1992). A meta-analysis showing a survival benefit from thoracic radiotherapy in LD-SCLC.
   Google Scholar
• Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl. J. Med. 341,476–484 (1999).
   PubMed Web of Science ®Google Scholar
• ••A meta-analysis offering insight into thedegree of benefit from prophylactic cranial irradiation.
   Google Scholar
• Wall ME, Wani MC, Cook CE eta]. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am. Chem. Soc. 88,3888–3890 (1966).
   Google Scholar
• ••This is the first report on the isolation andstructure of camptothecin.
   Google Scholar
• Masuda N, Kudoh S, Fukuoka M. Irinotecan (CPT-11): pharmacology and clinical applications. Grit. Rev. Oncol Hematol 3–26 (1996).
   Google Scholar
• •A comprehensive review of the preclinical and clinical studies of CPT-11.
   Google Scholar
• Hsiang Y-H, Liu LE Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48,1722–1726 (1988).
   PubMed Web of Science ®Google Scholar
• ••This report first to show thattopoisomearse I is a target of camptothecin. The finding renewed interest in camptothecin.
   Google Scholar
• Jaxel C, Kohn KW, Wani MC et al Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and relation to antitumor activity. Cancer Res. 49,1465–1469 (1989).
   PubMed Web of Science ®Google Scholar
• Yang J, Han J, Xu B. Distribution and excretion of 10-hydroxycamptothecin and its influence on the immune response. Acta Pharmacol Sin. 1,44-48 (1980).
   Google Scholar
• Creasey WA, Richards M, Tsou K. Action of (5)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice. Cancer Treat. Rep. 67,179-182 (1983).
   Google Scholar
• Nagata H. Flow cytometric analysis of the effect of an antitumor alkaloid, camptothecin, on cell cycle progression of KB cells. J Aichi Med. Univ. Assoc. 15, 683–699 (1987).
   Google Scholar
• Kunimoto T, Nitta K, Tanaka T et al. Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors. J Pharmacobio-Dyn10, 148–151 (1987).
   Google Scholar
• Kunimoto T, Nitta K, Tanaka T et al. Antitumor activity of 7-ethyl-10- [4- (1-PIPERIDINO)-1-PIPERIDIN01-carbonyloxy-camptothecin, a novel water- soluble derivative of camptothecin, against murine tumors. Cancer Res. 47,5944-5947 (1987).
   Google Scholar
• •This is the first report showing antitumor activity against various murine tumors.
   Google Scholar
• Matsuzaki T, Yokokura T, Mutai M et al. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol 21,308–312 (1988).
   Google Scholar
• Tsuruo T, Matsuzaki T, Matsushita M et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitm and in viva Cancer Chemother. Pharmacol 21,71–74 (1988).
   Google Scholar
• Tsuji T, Kaneda N, Kado K et al CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobio-Dyn 14,341–349 (1991).
   Google Scholar
• Kawato Y, Aonuma M, Hirota Y et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187–4191 (1991).
   PubMed Web of Science ®Google Scholar
• •This study shows that SN-38 has 1000-fold increased antitumor activity compared with CPT-11 in vitro and plays an essential role in the cytocidal activity and toxicity of the parent compound, suggesting that CPT-11 is a prodrug.
   Google Scholar
• Abigerges D, Armand J, Chabot G et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl Cancer Inst. 86, 446–449 (1994).
   Google Scholar
• ••This study showed that high-doseroperamide is a useful method to control delayed-onset diarrhea.
   Google Scholar
• Ando Y, Saka H, Asai G et al UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol 9,845–847 (1998).
   Google Scholar
• Abigerges D, Chabot GG, Armand JP et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. I Clin. Oncol 13,210–221 (1995).
   Google Scholar
• Muggia F, Creaven P, Hansen H et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. 56,515-521 (1972).
   Google Scholar
• Furuta T, Yokokura T Effect of administration schedule on the antitumor activity of CPT-11, a camptothecin derivative. Can-To-Kagakuryoho 17,121–130 (1990).
   PubMedGoogle Scholar
• Negoro S, Fukuoka M, Masuda N et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. I Natl Cancer Inst. 83,1164-1168 (1991).
   Google Scholar
• ••This is the first Phase I trial of CPT -11 inpatients with lung cancer, showing that the recommended dose for Phase 11 trials is 100 mg/m2 on a weekly schedule.
   Google Scholar
• Rothenberg M, Kuhn J, Burris III H et al Phase land pharmacokinetic trial of weekly CPT-11. Clin. Oncol 11,2194–2204 (1993).
   Google Scholar
• Gandia D, Armand J, Chabot G et al Phase I study of the new camptothecin analogue CPT-11 administered every 3 weeks. Proc. Am. Assoc. Cancer Res. 33,260 (1992).
   Google Scholar
• Negoro S, Fukuoka M, Niitani H et al Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol 10,241 (1991).
   Google Scholar
• Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. I Clin. Oncol 10, 1225–1229 (1992).
   Google Scholar
• •A Phase II trial reported on CPT-11 as a second-line therapy. A response rate of 47% was observed.
   Google Scholar
• Le Chevalier T, Ibrahim N, Chomy P et al. A Phase II study of irinotecan (CPT-11) in patients (pts) with small-cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT). Proc. Am. Soc. Clin. Oncol 16,450a (1997).
   Google Scholar
• DeVore RF, Blanke CD, Denham CA et al. Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol 17,451a (1998).
   Google Scholar
• Kudoh S, Takada M, Masuda N et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin and cisplatin against human lung tumor xenografts. Jpn. Cancer Res. 84,203-207 (1993).
   Google Scholar
• Zwelling L, Kohn K. Mechanism of action of cis-dichloro-diammineplatinum (H). Cancer Treat Rep. 63,1439–1444 (1979).
   PubMedGoogle Scholar
• Gottlieb J, Drewinko B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother. Rep. 59, 621–628 (1975).
   PubMedGoogle Scholar
• Masuda N, Fukuoka M, Kudoh S et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for
   Google Scholar
• •• advanced lung cancer. BE j Cancer 68, 777–782 (1993).
   Google Scholar
• Kudoh S, Fujiwara Y, Takada Y et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J. Clin. Oncol 16,1068–1074 (1998).
   PubMed Web of Science ®Google Scholar
• ••A Phase 11 trial of cisplatin and CPT -11demonstrated that the median survival time was 14.3 months for LD patients and 13.0 months for ED patients. Very promising survival data were obtained, especially in ED-SCLC patients.
   Google Scholar
• Okishio K, Furuse K, Kawahara M et al. A Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in previously treated small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol 17,497a (1998).
   Google Scholar
• Nakanishi Y, Takayama K, Takano K eta]. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am. J. Clin. Oncol 22,399–402 (1999).
   Google Scholar
• Kano Y, Suzuki K, Akutsu M et al Effects of CPT-11 in combination with other anticancer agents in culture. int. J. Cancer 50, 604–610 (1992).
   Google Scholar
• Takada M, Fukuoka M, Kudoh S et al Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Floc. A117. Assoc. Cancer Res. 33,226 (1992).
   Google Scholar
• Masuda N, Fukuoka M, Kudoh S et al. Phase land pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol 12,1833–1841 (1994).
   PubMed Web of Science ®Google Scholar
• Masuda N, Matsui K, Negoro S et al Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. j Clin. Oncol 16, 3329–3334 (1998).
   PubMed Web of Science ®Google Scholar
• •A Phase II trial of CPT-11 and etoposide in previously treated SCLC patients. An overall response rate of 71% and median survival time of 271 days were obtained.
   Google Scholar
• Nakamura S, Kudoh S, Komuta K et al. Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small-cell lung cancer (ED-SCLC): A study of the West Japan Lung Cancer Group. Proc. Aim Soc. Clin. Oncol 18,470a (1999).
   Google Scholar
• Rushing DA. Phase VII study of weekly irinotecan and paclitaxel in patients with SCLC. Oncol 14\(Suppl. 5), 63–66 (2000).
   Google Scholar
• Fujita A, Takabatake H, Tagaki S eta]. Combination of cisplatin, ifosfamide and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology59,105–109 (2000).
   Google Scholar
• Noda K, Nishiwaki Y, Kawahara M et al Randomized Phase III study of irinotecan (CPT-11) and cisplatin versusetoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study (JC0G9511). Proc. Am. Soc. Clin. Oncol 19, 483a (2000).
   Google Scholar
• ••The preliminary data of the firstrandomized trial evaluating a combination of CPT-11 and cisplatin in ED-SCLC. The study was halted prematurely due to the superiority of CPT-11 and cisplatin to cisplatin and etoposide in terms of response rate and survival.
   Google Scholar
• Lynch TJ. Lung cancer highlights. Oncologist 5,274–279 (2000).
   PubMedGoogle Scholar
• Chute JP, Chen T, Feigal E et al. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol 17, 1794–1891 (1999).
   PubMed Web of Science ®Google Scholar
• •An excellent overview of all US cooperative group trials in ED-SCLC from 1972 to 1993. The overall survival has changed little since the introduction of combination chemotherapy regimens in the late 1970s.
   Google Scholar
• Tamura K, Takada M, I K et al Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.Jpn.j Cancer Res. 88,218–223 (1997).
   PubMedGoogle Scholar